Robinan Gentry has over 20 years of experience in toxicological issues relevant in the determination of the potential safety or risk associated with exposure to chemicals in consumer products, pharmaceuticals or the environment. Over her career, she has been a principal investigator or contributing author for numerous safety and risk assessments for both government and industry. The purpose for a number of these assessments has been to incorporate innovative quantitative approaches in the determination of acceptable levels of exposure of humans to chemicals in the environment, in pharmaceuticals, and in consumer products. She is a published author in the development of Physiologically Based Pharmacokinetic (PBPK) models, and their application into both the cancer and non-cancer risk assessment process. She has also been involved in projects using these types of models to investigate human variability by age and gender and the potential impact of this variation on risk assessment. Her recent work includes projects that are aimed at understanding the mode of action of adverse effects in animals and the implications to human health, as well as the development of innovative approaches that rely upon in vitro data and incorporation of these data into the risk assessment paradigm.